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INTRODUCTION 
1. The Circulatory System and Homeostasis 
The survival of any metazoan specie is dependent upon continuous oxygen supply. In more 
primitive organisms, consisting of several hundred up to a few thousands of cells (e.g. 
C.elegans), oxygen is distributed by simple diffusion. In more complex species the increased 
biological complexity brought upon by selection and evolution, lead to the need for specialized 
systems of conduits capable of delivering oxygen and nutrients to distant organs, along with the 
removal of metabolic wastes1. In higher vertebrates, these vital functions are carried out by the 
circulatory system, which comprises the cardiovascular system, distributing blood, and the 
lymphatic system, circulating the lymph2. A network of blood vessels containing carrier 
molecules assemble a closed circuit where blood is pumped around the body through arteries 
and returned though veins, both of which ramify into arterioles and venules, respectively, and 
further into capillaries2. Capillaries form interweaving networks called capillary beds, that 
surround the tissues and establish a surface for the exchange of gases and nutrients, closing the 
circulatory loop between the arterial and the venous systems2. Due to the arterial pressure 
imposed by the system, blood plasma continuously leaks from the capillaries into the 
extracellular space3. In order to maintain the fluid balance in the tissue, the extravasated fluid 
(interstitial fluid) that cannot be osmotically re-absorbed at site, is drained by the lymphatic 
system (as lymph), via lymphatic vessels and capillaries, and ultimately returned back to the 
venous circulation3. This lymph, rich in proteins, lipids, immune cells, and any foreign material 
present in it, is filtered along the way through a chain of lymph nodes, granting the lymphatic 
system a crucial role in the immune defence4.  
The formation and further maintenance of a complex, highly organized and functionally 
competent vascular network is therefore a key component to homeostasis. 
2. Early Blood Vascular Development and Maturation of Blood Vessels 
The entire circulatory system is lined by interconnected, tube-forming, endothelial cells (ECs). 
In a gastrulating embryo, ECs differentiate from mesodermal-derived EC percursors, or 
angioblasts5–7, to form a primitive network of rather uniformly sized EC channels in a process 
known as vasculogenesis8–10. This primitive vascular network then progressively expands 
through the formation of new vascular segments originating from existing vessels, remodelling 
into a highly organized network of larger vessels that ramify into smaller ones9,11. There are 
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two processes by which new vessels are formed from the pre-existing vasculature: i) by 
intussusception, the splitting of vessels through the insertion of tissue pillars and ii) by 
(sprouting) angiogenesis whereby new vessels sprout from the ends and sides of the pre-
existing ones; either of which may then split and branch into lower calibre vessels8,9,11–13. After 
expansion of the nascent capillary bed, the EC channels mature into a system of stable vessels. 
Maturation of the neovessels involves recruitment of mural cells (pericytes and smooth muscle 
cells) to form the surrounding vessel wall, granting stability to the vessel, a process named 
arteriogenesis8,14,15. This process depends highly on the physiological function of the vessel, 
regarding the tissue it nurtures. Small blood vessels consist of only ECs, whereas larger vessels 
are surrounded by mural cells: pericytes in medium-sized and smooth muscle cells (SMCs) in 
large vessels15. Additionally, collateral growth denotes the expansive growth of pre-existing 
vessels, forming collateral bridges between arterial networks14,16.  
During the maturation process, ECs become phenotypically and functionally specialized in 
order to assure proper integrity and architecture of the circulatory system, as well as to perform 
their necessary functions17,18. It is a combination of hard-wired genetic programming and 
extrinsic signals that determines the specialization of the endothelium to arterial, venous, 
hemogenic and lymphatic subtypes19. For instance, arteries are supported by layers of vascular 
SMCs and a specialized matrix, whereas veins are thinner and surrounded by fewer SMCs13,15. 
Their structures reflect the differences in hemodynamic load to which they are subject. Arteries 
face high pressure gradients enabling transportation of blood to capillaries whereas veins face 
low pressure gradients13. Moreover, arterial and venous ECs possess specific molecular 
identities17. For instance, Notch pathway components are highly expressed in arteries but low 
in veins20–22. Disruption of Notch signalling causes loss of arterial markers and re-expression 
of venous signature genes, suggesting that Notch promotes arterial specification by repressing 
venous identity23–28. 
Disrupting the normal program of vascular development often results in disease phenotypes or 
even embryonic lethality. 
3. Angiogenic sprouting 
The first step in the angiogenic process requires the activation of ECs by angiogenic signals, 
such as vascular endothelial growth factors (e.g. VEGF, VEGFC), angiopoietins (e.g. 
ANGPT2), fibroblast growth factors (FGFs) and/or chemokines29. When a quiescent vessel 
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senses an angiogenic signal, cell-cell junctions and the basement membrane (BM) are 
remodelled30 in part by matrix metalloproteinases (MMPs) and mural cells detach allowing an 
activated EC, tip cell, to migrate in response to guidance signals31. ECs become motile and 
invasive and protrude filopodia32. Trailing behind tip cells, stalk cells extend fewer filopodia 
but establish a lumen and proliferate to support sprout elongation33–35. Tip cells anastomose 
with cells from neighbouring sprouts to build vessel loops36,37. The initiation of blood flow, the 
establishment of a basement membrane, and the recruitment of mural cells stabilize new 
connections13,38. The sprouting process iterates until proangiogenic signals abate, and 
quiescence is re-established13,14,39–41 (Figure 1). 
 
 
 
Figure [1] Molecular basis of vessel branching. a. Initial steps of tip cell selection. Vascular sprouting is initiated 
by proangiogenic factors (e.g. VEGF). ECs at the leading edge of the vascular sprout extend filopodia and migrate 
toward angiogenic signals. VEGF activates VEGFR-2 to stimulate tip cell migration. The coreceptor NRP1 
complexes with and enhances VEGFR-2 signalling. ECs become either the migratory vessel-leading tip cell or the 
proliferating stalk cell, but their phenotype is fluid; Notch regulates this specification. ECs with activated VEGFR-
2 signalling compete for the tip cell position by increasing their expression of DLL4, which binds to Notch 
receptors on neighbouring ECs, releasing the transcription regulator NICD. NICD transcriptionally downregulates 
VEGFR-2 and NRP1 expression while increasing VEGFR-1, a VEGF trap, thus enhancing the stalk cells’ 
unresponsiveness to VEGF. The tip cell is not a fixed position, and fluidity at the front occurs depending on the 
VEGFR-1/VEGFR-2 ratio. Tip cell migration requires BM degradation (in part due to MMP), EC junction 
loosening (caused by VE-cadherin, ZO1, and others), and pericyte detachment (regulated by ANGPT2). VEGF 
increases the permeability of the vessel, allowing the extravasation of plasma proteins (e.g., fibronectin and 
fibrinogen) that are deposited as a provisional matrix layer while the pre-existing interstitial matrix is remodelled 
by proteases; these events enable tip cell migration. b. Tip cell guidance and stalk elongation. The growing sprout 
moves along a VEGF gradient. Tip cells adhere to the ECM, mediated by integrins, and migrate toward guidance 
signal molecules (e.g., semaphorins and ephrins). Stalk cells trail behind the tip cell and proliferate to allow sprout 
elongation and lumen formation. While Notch signalling inhibits proliferation, expression of NRARP at branch 
points allows Wnt signalling to maintain stalk cell proliferation. This system allows vascular 
migration/directionality (by tip cells) and elongation of the shaft (by proliferating stalk cells). When two tip cells 
meet, they fuse (anastomose); this mechanism is assisted by macrophages, which accumulate at sites of vascular 
anastomosis to act as bridge cells by interacting with the neighbouring tip cells’ filopodia. Once contact between 
the tip cells has been established, VE-cadherin–containing junctions further strengthen the connection. 
Perivascular macrophages further stimulate sprouting by producing angiogenic factors or proteolytically liberating 
them from the ECM. The stalk cells also deposit BM and recruit pericytes, thus stabilizing the forming vessel. 
Pericyte precursors are attracted to vessels by EC-expressed PDGF. Once at the vessel, these mesenchymal 
precursor cells differentiate to pericytes in response to TGFβ and decrease EC migration, proliferation, and 
vascular leakage, resulting in nascent vessel stabilization. c. Maturation through resolution of quiescent phalanx 
cells. Once fusion has occurred, a connected lumen is formed to allow blood flow through the new vessel. This 
perfuses the hypoxic tissue, and the resultant oxygen and nutrient delivery leads to decreased levels of angiogenic 
signals, inactivation of EC oxygen sensors, and increased proquiescent molecules that lead to EC quiescence. 
Establishment of the blood flow remodels vessel connections, which are regulated by the shear stress–responsive 
transcription factor KLF2. ECs resume a quiescent phalanx phenotype in a tightly apposed monolayer with a 
streamlined surface that conducts the blood flow and regulates tissue perfusion. Perfusion induces vascular 
maturation by reestablishment of cell-cell junctions, pericyte maturation, and BM deposition. Autocrine and 
paracrine signalling from ECs and surrounding support cells by VEGF, FGF, ANGPT1, and Notch, among others, 
maintain a quiescent EC phenotype and protect the vessel from environmental stresses. Reduced growth factor 
signalling can lead to vessel retraction and EC apoptosis. Once stabilized and matured, the vessel forms a barrier 
between the blood and surrounding tissue, controlling the exchange of fluids and solutes. Adapted from Welti et 
al. (2013). 
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4. Angiogenic Regulators 
Functional angiogenesis requires a complex coordination of steps, which are regulated by a 
fine-tuned balance of angiogenic inducers and inhibitors42–46. Table [1] for a selective list of the 
main stimulators and inhibitors that take part in the angiogenic response. 
Table [1] List of the main angiogenic stimulators and inhibitors. 
Angiogenic Stimulators Angiogenic Inhibitors 
Angiogenin 
Angiopoietins (ANGPTs) 
Angiotropin  
Cysteine-rich protein 61 (CYR61) 
Ephrin 
Epidermal growth factor (EGF) 
Erythropoietin (EPO) 
Fibroblast growth factors (FGFs) 
Hepatocyte growth factor (HGF) 
Insuline-like growth factor (IGF) -1 
Integrins 
Interleukin (IL) -8 
Matrix metalloproteinases (MMPs) 
Nitric Oxide (NO) 
Platelet endotelial cell adhesion molecule (PECAM) -1 
Platelet-derived endothelial growth factor (PDGF) 
Transforming growth factor (TGF) -β * 
Vascular endothelial (VE)–cadherin  
Vascular endothelial growth factor (VEGF) 
Angiopoietin (ANGPT) -2 
Angiostatin 
Arresten 
Endostatin 
Interferon (IFN) -α, -β, -γ 
Interleukin (IL) -12 
Platelet factor (PFA) -4 
Thrombospondin (TSP) -1, -2 
Tissue inhibitors of metalloproteinase (TIMP) -1, -2, -3 
Transforming growth factor (TGF) -β * 
 
 
 
* Can show opposite effects depending upon doses and environmental conditions 
4.1. The angiopoietin family  
The human angiopoietin (ANGPT) family consists of four members, ANGPT1, ANGPT2, 
ANGPT3 and ANGPT4, which bind to specific tyrosine kinase receptors with immunoglobulin-
like and EGF-like domains (TIE) -1 and -2 (TIE1 and TIE2)44.  
ANGPT1 induces EC survival, capillary sprouting and pericyte recruitment47. By increasing 
the interaction between ECs and pericytes, ANGPT1 is known to stabilize blood vessels48. In 
vivo, studies suggest that ANGPT1 is essential for maturation and stabilization of the 
developing vasculature and for normal remodelling, since mice lacking Angpt1 start to develop 
a primary vasculature which fails to stabilize or remodel leading to embryonic lethality49. On 
the other hand, ANGPT2 can either promote or inhibit vessel growth, depending on the presence 
of other growth factors, such as VEGF47. ANGPT2 was first described to block ANGPT1‐
mediated TIE2 receptor activation, acting as an antiangiogenic factor capable of promoting EC 
5 
 
apoptosis and blood vessels regression in vivo50. Intriguingly, subsequent studies have shown 
that higher expression levels of ANGPT2 are associated to sites of vascular remodelling in 
adults, in particular in the female reproductive tract and in highly vascularised tumours51,52. In 
fact, it has been suggested that, by antagonizing the stabilizing influence of ANGPT1, ANGPT2 
might provide a key destabilizing signal reverting vessels to a more plastic state48. Such 
destabilized vessels could then be prone to: regression in the absence of growth factors; or 
alternatively, angiogenic sprouting mediated by available angiogenic factors such as VEGF. 
Further investigations have demonstrated that, in the presence of VEGF, ANGPT2 is 
responsible for an increase in capillary diameter, migration and proliferation of ECs, and 
sprouting of new blood vessels53. Additionally, high levels of ANGPT2 can induce TIE2 
phosphorylation in human umbilical vein endothelial cells (HUVEC), stimulating cell 
proliferation, cell differentiation and protection against induced cell death54,55. ANGPT2‐
induced TIE2 phosphorylation has also been demonstrated in murine brain capillary ECs, 
promoting migration and tube-like structure formation56. 
4.2. The fibroblast growth factor family 
The fibroblast growth factor (FGF) family consists of at least 18 members, to which four high-
affinity tyrosine-kinase receptors (FGFRs) have been described57. The most studied forms are 
FGF2 (or basic FGF, bFGF) and FGF1 (or acidic FGF, aFGF), which most commonly bind to 
FGFR1 and FGFR2, on ECs57.  
In vitro studies have shown that stimulation of FGF1 and FGF2 induces proliferation, 
migration, survival, and differentiation of ECs58,59. The angiogenic activity of recombinant 
FGF1 and FGF2 proteins has been demonstrated in various in vivo models, including the 
avascular rabbit or mouse cornea60, mice subcutaneous matrigel injection61, and the chicken 
chorioallantoic membrane (CAM) assay62.  FGF2 has also been reported to up‐regulate the 
expression of several proangiogenic molecules, such as MMPs, αvβ3 integrin, VEGF and 
HGF44,58. Studies using knockout mice have demonstrated essential functions for FGFR1 and 
FGFR2 in early development63.  Moreover,  Fgf2 and Fgf1/Fgf2 knockout mice exhibit delays 
in the remodelling of damaged blood vessels during wound healing and tumour angiogenesis58. 
Additionally, tube formation stimulated by VEGF is totally abolished when neutralizing 
antibodies to FGF2 are added to the system, showing that in this particular setting, VEGF 
requires the presence of FGF2 for promoting vessel assembly64. FGF signalling also contributes 
to the proliferation of tumour cells either by an autocrine or paracrine mechanism57,64 
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4.3. The hepatocyte growth factor family 
The hepatocyte growth factor (HGF) is a mesenchyme-derived pleiotropic factor65, which 
regulates cell growth66, cell motility66,67, and morphogenesis of various types of cells and is 
thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for 
morphogenic tissue interactions during embryonic development and organogenesis68,69. 
Although HGF was originally identified as a potent mitogen for hepatocytes70, it has also been 
identified as a member of the angiogenic factors.  
HGF, together with its tyrosine kinase receptor, C-MET71, have been associated with most types 
of human cancers. Their expression often correlates with poor prognosis and metastases72,73. 
Multiple biological outcomes of HGF–Met signalling account for its role in cancer, among 
which the most critical are cell proliferation, tumour cell invasion, and angiogenesis74. HGF is 
angiogenic: the ligand–receptor interaction stimulates ECs to proliferate and migrate in vitro66, 
induces blood vessel formation in vivo75, and induces the VEGF expression in human cancer 
cells. It was shown that HGF–Met signalling operates as a key switch, turning on VEGF and 
turning off TSP-1 expression and thus invoking angiogenesis76. Recent studies have 
demonstrated the potential application of HGF to treat cardiovascular diseases such as 
peripheral vascular disease, myocardial infarction and cerebrovascular disease77. 
4.4. The platelet-derived growth factor family 
The platelet-derived growth factor (PDGF) family comprises four members: PDGF -A, -B, -C, 
-D, binding with distinct selectivity to the receptor tyrosine kinases PDGFRα and PDGFRβ, 
expressed on ECs and SMCs78. The PDGFB/ PDGFRβ signalling is an important regulator of 
the blood vessel maturation38. PDGFB secreted by ECs in response to VEGF recruits mural 
cells to the growing vessels by signalling through PDGFRβ79,80. In agreement, Pdgfβ -/- and 
Pdgfrβ -/- knockout mice are embryonic lethal presenting severe haemorrhage and oedema due 
to the failure of immature vessels to attract pericytes80. PDGFC promotes vascular development 
in the embryo and in wound healing, as well as angiogenesis in avascular tissues81, whereas 
PDGFD is involved in tumour neovascularisation82.  
4.5. The transforming growth factor-β family 
The transforming growth factor-β (TGFβ) and its receptors are expressed in a broad spectrum 
of cell types, including tumour cells, pericytes and ECs, acting both in a paracrine and autocrine 
fashion. 
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TGFβ binds to two different types of serine-threonine kinase receptors, known as type I 
(TGFβR1) and type II (TGβR2). TGFβR1 and TGFβR2 are interdependent, meaning that 
TGFβR1 requires TGFβR2 to bind TGFβ and TGFβR2 requires TGFβR1 for signaling44,83. 
The most well studied member of this family is the TGFβ1, being its biological function highly 
dose- and microenvironment-dependent84. At low doses it contributes to the angiogenic switch, 
either indirectly, by inducing the upregulation of angiogenic factors (e.g. VEGF, FGF and 
PDGF, and proteinases)44,85; or directly, through the binding to the two types of TGFβR1: 
ALK1 and ALK5 (activin receptor‐like kinase ‐1 and ‐5, respectively) and consequent 
activation of proangiogenic or maturation-specific genes84. At high doses it inhibits EC 
proliferation and migration through down-regulation of angiogenic factors and up-regulation of 
TIMPs44,83.  
4.6. The vascular endothelial growth factor family 
The vascular endothelial growth factor (VEGF) family includes VEGF(-A), -B, -C, -D, and the 
placenta growth factor (PGF)86–88. VEGF (VEGFA) is the best characterized member of the 
family and the major mediator of normal and tumour angiogenesis45,89. Genetic studies have 
further demonstrated the importance of VEGF for normal vascular development since the loss 
of a single VEGF allele results in mice embryonic lethality90,91. VEGF is expressed in different 
tissues and circumstances88, with mRNA transcription reportedly induced by a number of 
factors including hypoglycaemia, mechanical forces of shear stress and cell stretch45,  other 
growth factors and cytokines (e.g. PDGF, EGF, TNFα, TGFβ and IL1β to name a few)91,92, 
hormones (e.g. estrogen and progesterone), but mostly and above all by hypoxia93.  
Hypoxia inducible factor 1 (HIF1)  is an oxygen-regulated transcriptional activator that 
functions as a master regulator of oxygen homeostasis94. HIF1 is a heterodimer, composed of 
HIF1α and HIF1β subunits94. Whilst HIF1β is constitutively expressed, HIF1α expression  is 
highly induced in hypoxic cells upon low O2 concentrations in the microenvironment 
94.In non‐
hypoxic conditions, HIF1α is ubiquitinated and subjected to proteosomal degradation94. Under 
hypoxic conditions, the fraction of HIF1α that is ubiquitinated decreases dramatically, resulting 
in an accumulation of the protein94. A functional hypoxia response element (HRE) in the 5’ 
region of the VEGF human promoter was found to bind the heterodimer HIF1α/HIF1β95. 
VEGF family members exert their biologic effect through binding to transmembrane tyrosine 
kinase receptors: VEGFR-1 and VEGFR-2, selectively expressed on vascular ECs96. 
Additionally, VEGF interaction with a class of co-receptors, neuropilin 1 (NRP1) and NRP2, 
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initially described as semaphorin receptors involved in axon guidance in the nervous system, 
has been shown to modulate the VEGF binding to the main receptors97. 
The binding affinity of VEGFR-1 for VEGFA is at least 10 fold higher than that of VEGFR-
298. However, despite binding VEGF with high affinity, VEGFR-1 presents weak tyrosine 
kinase phosphorylation activity following VEGF stimulation98. Experiments with mice lacking 
Vegfr-1 show that this receptor acts as a negative regulator of angiogenesis during embryonic 
development, as animals exhibit uncontrolled EC proliferation which results in the obstruction 
of vessel lumen and early lethality99. However, in adult, VEGFR-1 plays a role in activating 
VEGFR-2 and thereby in angiogenesis, binding of PGF100. This mechanism gains importance 
in angiogenesis‐associated pathologies, where PGF has often been described upregulated101. 
Furthermore, VEGFR-1 is involved in the preparation of the metastatic niche, since VEGFR-
1‐positive haematopoietic progenitor cells were shown to colonize tumour specific pre‐
metastatic sites prior to the arrival of tumour cells102. 
VEGFR-2 is considered the major mediator of the VEGF signalling during vasculogenesis and 
angiogenesis. Phosphorylated VEGFR-2-tyrosine residues serve as docking sites for molecules 
that initiate different signalling cascades leading to cellular responses such as proliferation, 
migration, survival and permeability. In pathologic conditions, VEGFR-2 promotes tumour 
angiogenesis, being highly expressed by several human cancer cells103. It has been shown that 
the blockage of VEGF activity leads to an inhibitory effect on the growth of many tumour cell 
lines in nude mice104,105. 
5. Physiological Angiogenesis 
In the embryo, blood vessels provide the growing organs with the necessary oxygen and 
nutrients to develop. After birth, despite still contributing to organ growth, most blood vessels 
remain quiescent and angiogenesis occurs only in specific situations, such as wound healing, 
the regeneration of the endometrium during the menstrual cycle or in the placenta during 
pregnancy1,106.  
Healthy adult ECs have long-half lives and are rendered quiescent by the action of maintenance 
signals. However, when an insult arises and physiological stimuli are released by environmental 
cues, such as hypoxia for blood vessels or/and inflammation for lymph vessels, such phenotype 
is rapidly shifted towards a motile, proliferative and evasive cell population, sending out sprouts 
in a coordinated directional manner14. ECs must therefore be equipped with a set of molecules 
that allow them to communicate with other cells within the vessel wall, and with cells inside 
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and outside of the lumen of the vessel, allowing them to sense changes in the blood flow and 
dynamically interact with the internal cytoskeleton and surrounding extracellular matrix, all in 
an integrated manner. 
6. Pathological Angiogenesis. 
When the dynamic equilibrium between pro- and antiangiogenic factors is further disrupted, 
vessel growth is deregulated, which may in turn have a major impact in health contributing to 
the pathogenesis of many disorders1,14,107. Impairment of blood vessel supply characterizes 
diseases like heart ischemia, hypertension, atherosclerosis, and diabetes1. Excessive growth on 
the other hand, has been implicated in diseases like cancer (and metastasis), age-related macular 
degeneration and rheumatoid arthritis1,107. Several congenital or inherited diseases have also 
been described to be caused by abnormal vascular remodelling14,46. Table [2] for a list of 
diseases characterized by excessive and insufficient angiogenesis. 
Table [2]. Diseases characterized by de-regulated Angiogenesis. Adapted from Carmeliet (2003) and Bhadada 
et al. (2010). 
Affected 
organ 
Diseases characterized by excessive 
angiogenesis 
Diseases characterized by insufficient 
angiogenesis 
Adipose 
tissue 
Obesity.   
Bone Synovitis; Osteomyelitis. Osteoporosis; Impaired fracture healing. 
Blood vessels 
 
DiGeorge syndrome; Hereditary 
hemorrhagic teleangiectasia (HHT); 
Cancer Metastasis; Cavernous 
hemangioma. 
Atherosclerosis; Hypertension; Diabetes; 
Peripheral arterial disease (PAD). 
Eye Persistent hyperplastic vitreous syndrome; 
Diabetic retinopathy; Retinopathy of 
prematurity; Aged-related macular 
degeneration; Choroidal 
neovascularisation. 
 
(Gastro)- 
intestinal 
Inflammatory bowel and periodontal 
disease; Peritoneal adhesions; Ulcerative 
colitis. 
Gastric or oral ulcerations; Crohn disease. 
Heart  Myocardial Ischemia; Myocardial hypertrophy. 
Lung Primary pulmonary hypertension; 
Asthma; Nasal polyps. 
Neonatal respiratory distress; Pulmonary 
fibrosis; Emphysema. 
Nervous 
system 
Von Hippel-Lindau disease (VHL). Alzeihmer disease; Amyotrophic lateral 
sclerosis; Diabetic neuropathy; Cerebral 
Ischemic Stroke. 
Reproductive 
system 
Endometriosis; Ovarian 
cysts/hyperstimulation and cysts. 
Preeclampsia. 
 
Skin Psoriasis; Scar keloids; Wound healing.  Hair loss; Lupus. 
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6.1. Peripheral Arterial Disease 
Peripheral arterial disease (PAD) is characterized by an occlusion in arterial beds, exclusive of 
the coronary, aortic arch or brain, restricting blood flow108,109. As a consequence, the nutritive 
requirements of the tissues beyond the occlusion point can only be met to a certain extent. PAD 
is a typical manifestation of systemic atherosclerosis, greatly affecting the circulation of the 
lower limbs108,109.  
The risk factors for PAD include diabetes mellitus, cigarette smoking, advanced age (>60/70), 
hyperhomocysteinemia, hyperlipidemia, hypercholesterolemia and hypertension110. These 
same risk factors are described for cardiovascular disorders, explaining in part the higher risk 
of cardiovascular morbidity and mortality associated with PAD patients111. The prevalence for 
PAD is high112–114 and is increasingly recognized as a health burden worldwide115.  
Critical limb ischemia (CLI) is the term used for patients with chronic ischemic rest pain, ulcers, 
or gangrene, attributed to inadequate blood flow or arterial occlusive disease109. It is the 
progressive evolution and clinical manifestation of peripheral arterial disease (PAD)109. 
CLI occurs when arterial lesions impair blood flow and distal perfusion pressure, to a level that 
is insufficient to satisfy the nutritive needs of the limb. This usually results from the presence 
of multilevel occlusive disease or occlusion of critical collaterals110. Moreover, in CLI, there is 
an inappropriate response of the microcirculatory flow regulatory mechanism due to 
microcirculatory defects that might include endothelial dysfunction, altered hemorheology and 
white blood cell activation and inflammation110. 
The primary goals of in the treatment of CLI are to relieve ischemic pain, heal ulcers, prevent 
limb loss, improve patient function and quality of life, and to prolong overall survival110.  
Any kind of surgical/endovascular revascularization, the therapy of choice in CLI patients, 
should be done whenever technically possible. Attempts to manipulate and normalize the 
microcirculatory flow pharmacologically may enhance the results of revascularization. In 
patients with CLI not eligible for arterial revascularization, prostanoids are vasoactive drugs 
with proven efficacy116,117. However, recent trials do not support the benefit of prostanoids in 
promoting amputation-free survival118. In a large proportion of CLI patients, the extent and 
anatomic distribution of arterial occlusive disease make the patients unsuitable for operative or 
percutaneous revascularization110. Amputation is often recommended as a solution to the 
disabling symptoms, even if it is associated to morbidity and mortality110.  The need for 
alternative treatment strategies in CLI patients is therefore compelling, and therapeutic 
angiogenesis is a promising tool to treat these patients. 
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7. Angiogenesis as a therapeutic target 
The scientific advances achieved on the molecular mechanisms that involve the angiogenic 
response, and/or develop disease, have triggered the path for the development of therapeutic 
strategies to promote angiogenesis119.  
The administration of angiogenic growth factors or inhibition of antiangiogenic factors, gene 
therapy to improve perfusion, and mobilization of stem cell populations, are some of the 
approached strategies to induce angiogenesis120–122. Therapeutic angiogenesis not only must 
ultimately lead to an increased neovascularisation, as the neovessels should be fully functional, 
stable and long-lasting.  
VEGF and FGF2 have been the growth factors mainly explored for this purpose; however many 
others have been studied (e.g. FGF1, FGF4, HGF). While many experimental studies are 
encouraging, randomized controlled clinical trials have produced less consistent results120. 
Although part of this failure is attributed to delivery procedure problems, the maintenance of 
long‐lasting strong and functional vessels remains a challenge. It is not clear if a single growth 
factor is sufficient to initiate the entire cascade of events leading to a mature, functional and 
stable vascular network in vivo (most growth factors secondarily induce other factors), or if a 
mix of growth factors should be used and precisely orchestrated over time106,120. Since HIFs 
initiate an entire angiogenic response, they have also been considered for angiogenic therapy123.  
Transplantation of endothelial progenitor cells (EPCs), derived from the bone marrow or 
peripheral blood, have demonstrated to be an alternative to angiogenic factors contributing to 
postnatal neovascularisation in ischemic limbs and myocardium124–127.  
Finally, therapeutic interventions that focus on the inhibition of natural antineovascularisation 
mechanisms should be considered (e.g. HGF inhibits endostatin and TSP-1)106,125. 
Nevertheless, successful proangiogenic therapy still raises some questions regarding long term 
side effects. If these therapies are able to significantly contribute to vessel integrity and repair, 
can they indirectly contribute to trigger dormant tumours and/or accelerate atherosclerosis? The 
different forms of therapeutic angiogenesis still have to prove safety and efficacy before one 
can conclude on its relevance as an additional limb saving strategy. It is still a long way from 
bench to bedside and patient benefit, despite a considerable number of ongoing clinical trials. 
Although the ability of IR in promoting therapeutic angiogenesis has never been investigated, 
it is interesting to note that doses of IR between 2 and 8 Gy were showed to induce the 
production of proangiogenic molecules, such as VEGF, TGFβ, FGF, IL-1R-a, IL10, IL3, IL4 
and IL5, by the tumoural cells, that may activate the microenvironment, including the 
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vasculature128–132. In addition, we found that the exposure of lung microvascular endothelial 
cells (HMVEC-L) to doses lower than 0.8 Gy enhances EC migration without impinging on 
cell proliferation or survival105. Moreover, it was found that low-dose IR activates the 
endothelium by phosphorylating the receptor-2 of the VEGF105, a critical player on the 
angiogenic process. It is described that the activation of VEGFR-2 leads to a rapid activation 
of different cellular proteins and consequently to the de novo mRNA and protein expression of 
mediators involved in the angiogenic response96,133. This is strongly supported by the data 
obtained in our lab from an in vitro microarray study where several transcripts encoding for 
proteins required for angiogenesis are induced upon low-dose IR delivery (unpublished results). 
The genes whose expression is significantly altered by low doses of IR and that represent the 
best candidates for a proangiogenic response were selected. Their expression was validated by 
quantitative real-time PCR (qPCR) and Western blot using irradiated and non-irradiated 
HMVEC-L. Unpublished results suggest that VEGFR-1, VEGFR-2, ANGPT2, FGF2, TGFβ 
have their expression increased in response to doses corresponding to 5 or 30 % of the 
therapeutic dose (100%). To validate these in vitro data, Sofia et al has shown that low doses 
of IR accelerates vessel formation by inducing angiogenic sprouting in fli1:EGFP embryos and 
increases vessel density in adult fli1:EGFP zebrafish.  
 
 
